Osteoprotegerin serum levels in multiple myeloma and MGUS patients compared with age- and sex-matched healthy controls [8]

Leukemia

Volumn 18, Issue 9, 2004, Pages 1555-1557

  Corso, A ^a   Dovio, A ^b   Rusconi, C ^a   Sartori, M L ^b   Klersy, C ^a   Varettoni, M ^a   Mangiacavalli, S ^a   Zappasodi, P ^a   Ventura, M ^b   Angeli, A ^b   Lazzarino, M ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DEXAMETHASONE; OSTEOPROTEGERIN; PAMIDRONIC ACID; PREDNISONE; CELL RECEPTOR; GLYCOPROTEIN; TNFRSF11B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGE; AGED; BLOOD SAMPLING; BONE ATROPHY; BONE DISEASE; CALCIUM BLOOD LEVEL; CANCER STAGING; CONTROLLED STUDY; CORRELATION FUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENDER; HUMAN; HUMAN CELL; LETTER; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OSTEOLYSIS; PLASMA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE; AGE DISTRIBUTION; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; HYPERGAMMAGLOBULINEMIA; MIDDLE AGED; SEX RATIO;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOPROTEINS; HUMANS; HYPERGAMMAGLOBULINEMIA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OSTEOPROTEGERIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; SEX DISTRIBUTION;

EID: 4444221213     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403429     Document Type: Letter

References (8)

1. Sezer O, Heider U, Zavrski I, Kuhne CA, Hofbauer LC. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003; 101: 2094-2098, Epub 2002 Nov 07.
2. Seidel C, Hjertner O, Abildgaard N, Heickendorff L, Hjorth M, Westin J et al. for Nordic Myeloma Study Group Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 2001; 98: 2269-2271.
3. Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003; 102: 1064-1069, Epub 2003 Apr 10.
4. Standal T, Seidel C, Hjertner O, Plesner T, Sanderson RD, Waage A et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 2002; 100: 3002-3007.
5. Ueland T, Bollerslev J, Godang K, Muller F, Froland SS, Aukrust P. Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess - possible role in bone homeostasis. Eur J Endocrinol 2001; 145: 685-690.
6. Kraj M, Centkowski P, Kruk B. Osteoprotegerin sRANKL serum levels in multiple myeloma patients. Haematol J 2003; 4: S157.
7. Scatena M, Giachelli C. The alpha(v)beta3 integrin, NF-kappaB, osteoprotegerin endothelial cell survival pathway. Potential role in angiogenesis. Trends Cardiovasc Med 2002; 12: 83-88.
8. Dovio A, Sartori ML, Angeli A. Correspondence re: A. Lipton et al, Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res 2002; 8: 2306-2310. Clin Cancer Res 2003; 9: 2384-2385.